#AZN

Lead report

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

AstraZeneca (AZN) Q2 results: non-GAAP EPS beats by $1.36 while revenue slightly misses despite 6.4% Y/Y growth.